The Opioid Crisis: Use and Misuse of Prescription, Illicit and Synthetic Opioids

Sandra Price (Editor)
Marc Bates (Editor)

Series: Alcohol and Drug Abuse
BISAC: PSY038000

Clear

$160.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Recently, there has been a rise in opioid use in the United States involving both the nonmedical use of prescription drugs and more traditional illicit opioids, such as heroin. The abuse of prescription opioid pain relievers and illicit opioids, have contributed to increasing numbers of overdose deaths in the United States, and Centers for Disease Control and Prevention data show more than 28,000 opioid overdose deaths in 2014. Chapter 1 reports that medication-assisted treatment (MAT) can more effectively reduce opioid use and increase treatment retention compared to treatment without medication. There has also been a significant increase in the use of man-made (synthetic) opioids, such as fentanyl and fentanyl analogues, as described in chapter 2. Synthetic opioids like fentanyl—a substance 100 times stronger than morphine—accounted for more than 19,000 of the nearly 64,000 overdose deaths in 2016, the most recent year for which federal data are available. Misuse of prescription opioids can lead to overdose and death. Medicare and Medicaid, two of the nation’s largest health care programs, provide prescription drug coverage that can include opioids. Chapter 3 discusses the inappropriate activities and risks associated with these prescriptions. Chapter 4 gives examples of some policy options that could be employed for training on safe opioid prescribing. Buprenorphine is a medication used to treat adults addicted to opioids (it is also used in the treatment of pain). Buprenorphine’s effectiveness, safety, and availability in the treatment of opioid addiction are of considerable interest to policymakers seeking to address the ongoing opioid epidemic in the United States as seen in the last chapter.

Preface

Chapter 1. Illicit Opioids: While Greater Attention Given to Combating Synthetic Opioids, Agencies Need to Better Assess their Efforts
GAO

Chapter 2. Prescription Opioids: Medicare Needs Better Information to Reduce the Risk of Harm to Beneficiaries
Statement of Mary Denigan-Macauley

Chapter 3. Policy Options to Increase Physician Training Education in Proper Opioid Prescribing
Elayne J. Heisler

Chapter 4. Opioid Addiction: Laws, Regulations, and Other Factors Can Affect Medication-Assisted Treatment Access
GAO

Chapter 5. Buprenorphine and the Opioid Crisis: A Primer for Congress
Johnathan H. Duff

Index

You have not viewed any product yet.